J&J shares rise on Caplyta bipolar mania endpoint result
Johnson & Johnson shares gained about 0.8% to $272.34 Monday after Caplyta hit its primary endpoint in a late-stage bipolar mania study, prompting investors to weigh potential expansion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.